Aurinia Pharmaceuticals (NASDAQ:AUPH) Cut to Buy at StockNews.com

StockNews.com cut shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) from a strong-buy rating to a buy rating in a report issued on Friday morning.

Other analysts have also recently issued reports about the stock. HC Wainwright reissued a “buy” rating and issued a $13.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Friday, September 6th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $10.00 price target on shares of Aurinia Pharmaceuticals in a research note on Monday, September 16th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $10.00.

Aurinia Pharmaceuticals Trading Down 3.3 %

Shares of NASDAQ:AUPH opened at $9.37 on Friday. The stock has a 50 day moving average of $8.03 and a 200 day moving average of $6.75. The company has a market cap of $1.34 billion, a PE ratio of -62.46 and a beta of 1.41. Aurinia Pharmaceuticals has a 12-month low of $4.71 and a 12-month high of $10.67. The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.17.

Insider Transactions at Aurinia Pharmaceuticals

In related news, Director Jeffrey Allen Bailey sold 4,557 shares of the firm’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $8.43, for a total transaction of $38,415.51. Following the completion of the transaction, the director now directly owns 13,356 shares of the company’s stock, valued at approximately $112,591.08. This trade represents a 25.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in AUPH. SG Americas Securities LLC grew its holdings in Aurinia Pharmaceuticals by 4,307.9% during the 3rd quarter. SG Americas Securities LLC now owns 547,727 shares of the biotechnology company’s stock valued at $4,015,000 after buying an additional 535,301 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Aurinia Pharmaceuticals in the third quarter valued at $3,330,000. Stonepine Capital Management LLC bought a new stake in Aurinia Pharmaceuticals in the second quarter worth $1,713,000. AQR Capital Management LLC purchased a new stake in Aurinia Pharmaceuticals during the second quarter valued at $1,155,000. Finally, Barclays PLC lifted its position in Aurinia Pharmaceuticals by 187.6% during the third quarter. Barclays PLC now owns 219,331 shares of the biotechnology company’s stock valued at $1,607,000 after purchasing an additional 143,072 shares during the last quarter. Institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.